Authors

Latest:

Dr. Richardson on the Use of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

Kristin Rojas, MD

Latest:

Turning the Tide on Opioid Prescribing Practices

As evidence grows that opioids may potentially worsen oncologic outcomes, surgeons and oncology providers must take an active role in addressing the opioid crisis by adopting similar protocols that decrease the quantity of narcotics available for diversion while ensuring safe patient care.

Kristopher Bosse, MD

Latest:

Dr. Bosse on Immunotherapy in Pediatric Cancers

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the use of immunotherapy in the treatment of pediatric patients with cancer.

Krithika Subramanian, PhD

Latest:

TILs Show Growing Potential as Novel Immunotherapy

Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.

Krystal Knapp

Latest:

The Great Biomarker Chase: Promise & Pitfalls Along the Path to Personalized Care

Biomarkers offer great potential for improving management of cancer at every point from screening and detection, to diagnosis, staging, prognosis, and the assessment of treatment response.

Krystal Knapp, Ben Leach

Latest:

The Year's New Drugs: Integrating Advances of 2011 Into Treatment Plans

The FDA approved more new oncology drugs in 2011 than it has in a single year in more than a decade, thanks in part to priority review and streamlined evaluation procedures. While this is good news for patients, oncology and hematology specialists must tackle the challenges posed by integrating new therapies into treatment plans. Leading specialists give their perspectives on key issues.

Kumar Sankhala, MD

Latest:

Dr. Sankhala on Challenges Facing the Treatment of Angiosarcoma

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses challenges facing the treatment of angiosarcoma.

Kunle Odunsi, MD, PhD, FRCOG, FACOG

Latest:

Proposed Trial Would Be First Ever for Novel Two-Pronged Immunotherapy Strategy

Roswell Park Cancer Institute is taking the final steps toward what we believe would be the first-ever clinical trial combining two novel and highly promising techniques: adoptive cellular therapy utilizing re-engineered mature T cells and re-engineered adult hematopoietic stem cells.

Kuo Bianchini Tong, MS

Latest:

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Kurt Tauer, MD, FACP

Latest:

Dr. Tauer on Arguments in Favor of and Against Biosimilars in Oncology

Kurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.

Kurt Ullman

Latest:

Practice Benchmark Report Offers Hope for Survival of Independent Oncology Practices

The narrowing difference between operating cost and total medical revenue has eased, buying some time for practices to adjust their business models and perhaps survive.

Kurt W. Tauer, MD, FACP

Latest:

Dr. Tauer on the Expansion of Subtyping in Breast Cancer

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Kwok-Kin Wong, MD, PhD

Latest:

Dr. Wong on the Current Landscape of NSCLC

Kwok-Kin Wong, MD, PhD, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine, and director of the Division of Hematology and Medical Oncology at NYU Langone’s Perlmutter Cancer Center, discusses the current landscape of non–small cell lung cancer (NSCLC).

Kyle A. Richards, MD

Latest:

Dr. Richards on Unanswered Questions in Treating Bladder Cancer

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Laila Saied Agrawal, MD

Latest:

Dr Agrawal on First-Line Treatment Approaches in HER2+ Breast Cancer

Laila S. Agrawal, MD, discusses the primary approaches for treating patients with metastatic HER2-positive breast cancer, and highlights the continued exploration of trastuzumab deruxtecan for this patient population.

Lajos Pustzai, MD, DPhil

Latest:

Dr. Pusztai on the Promise of ctDNA Assays in Breast Cancer

Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.

Lajos Pusztai, MD

Latest:

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Lajos Pusztai, MD, DPhil

Latest:

Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer

Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.

Lakshmi N. Rajdev, MD

Latest:

Dr. Rajdev on the Efficacy of Pembrolizumab/Chemotherapy in Esophageal Cancer

Lakshmi Rajdev, discusses the efficacy of pembrolizumab (Keytruda) plus chemotherapy in patients with esophageal cancer.

Lalan Wilfong, MD

Latest:

Dr Wilfong on the Potential Use of AI Prediction Models to Improve Palliative Care in Oncology

Lalan Wilfong, MD, expands on the value of AI prediction models for consensus on patient prognosis and better end-of-life care in oncology.